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Background and objectives: The Influenza Resistance Information Study (IRIS) was ini-
tiated in 2008 to study the emergence of neuraminidase inhibitor (NAI) resistance and 
the clinical course of influenza in immunocompetent treated and untreated patients.
Methods: Patients had throat/nose swabs collected on days 1, 3, 6 and 10 for analyses 
of influenza type, subtype and virus susceptibility to NAIs. RT- PCR- positive samples 
were cultured and tested for NAI resistance by specific RT- PCR and phenotypic test-
ing. Scores for influenza symptoms were recorded on diary cards (Days 1- 10). This 
study focuses on influenza A- infected cases only.
Results: Among 3230 RT- PCR- positive patients, 2316 had influenza A of whom 1216 
received oseltamivir monotherapy within 2 days of symptom onset (9 seasonal H1N1; 
662 H3N2; 545 H1N1pdm2009). Except for 9 patients with naturally resistant sea-
sonal H1N1 (2008/9), no resistance was detected in Day 1 samples. Emergence of 
resistance (post- Day 1) was detected in 43/1207 (3.56%) oseltamivir- treated influ-
enza A- infected patients, with a higher frequency in 1- to 5- year- olds (11.8%) vs 
>5- year- olds (1.4%). All N1- and N2- resistant viruses had H275Y (n = 27) or R292K 
(n = 16) substitutions, respectively. For 43 patients, virus clearance was significantly 
delayed vs treated patients with susceptible viruses (8.1 vs 10.9 days; P < .0001), and 
11 (23.2%) remained RT- PCR positive for influenza at Day 10. However, their symp-
toms resolved by Day 6 or earlier.
Conclusions: Oseltamivir resistance was only detected during antiviral treatment, with 
the highest incidence occurring among 1- to 5- year- olds. Resistance delayed viral 
clearance, but had no impact on symptom resolution.
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1  | INTRODUCTION
Neuraminidase inhibitors (NAIs) are the mainline therapy of influenza.1 
Through binding in the conserved catalytic domain of the enzyme, 
these drugs can inhibit all types and subtypes of influenza neuramin-
idase, but to varying degrees.2 In recent years, the human influenza A 
viruses have developed complete resistance to an older class of drugs, 
the adamantanes, indicating the ability of these viruses to develop 
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and subsequently maintain resistance to antivirals.3 In the first years 
of NAIs usage, following their introduction in 1999, naturally occur-
ring resistance was sporadically reported and a very limited number 
of cases were described.4-7 However, in 2008, naturally occurring 
oseltamivir resistance was detected among seasonal H1N1 viruses in 
Norway.8 This resistant virus eventually displaced the NAI- susceptible 
H1N1 virus rendering virtually all seasonal H1N1 viruses highly resis-
tant to oseltamivir.8,9 This emergence was not related to the use of 
antivirals.10,11 The resistant H1N1 virus was then replaced during the 
2009- 2010 pandemic by the influenza A H1N12009pdm virus, which 
was oseltamivir sensitive.12
As a consequence of this emergence and dissemination of an NAI- 
resistant virus, surveillance systems have been implemented to monitor 
antiviral susceptibility to NAIs. In this context, a global observational 
study was initiated in 2008, the Influenza Resistance Information Study 
(IRIS), to study the emergence of NAI resistance and the clinical course 
of influenza in immunocompetent treated and untreated patients.
The primary objective of the IRIS study was to assist with early 
detection of influenza resistance to antivirals and describe the clinical 
course and outcome of patients with influenza according to subtype 
and antiviral susceptibility.
Influenza Resistance Information Study is a prospective, multicentre, 
information- gathering study (NCT00884117). It is the largest study of 
its type that has collected sequential clinical and virological data during 
the course of infection, using sensitive RT- PCR detection methods for 
both detection of the virus and follow- up of substitutions associated 
with oseltamivir resistance in H1N1 and H3N2 viruses. Major findings 
of the first 3 years of this study have already been reported.13
This article reports the first 5 years of surveillance carried out 
through IRIS, with a specific focus on the description of the emer-
gence of influenza A- resistant viruses in treated patients, including the 
timeline of the emergence of the resistant viruses and the identifica-
tion of the substitutions associated with this resistance.
2  | MATERIAL AND METHODS
2.1 | Study design and conduct
Influenza Resistance Information Study (IRIS; NCT00884117) is a 
7- year prospective, multicentre, observational study. Recruitment 
started in December 2008 (Year 1), continued throughout the 2009- 
10 A/H1N1 influenza pandemic and until March 2013 (Year 5). After 
the 5th season, the study design was modified to continue for 2 ad-
ditional years (Years 6 and 7 until March 2015) with a different objec-
tive (focus on immunocompromised children only).
During the first 5 years of the study, inclusion centres were lo-
cated in Europe (France, Germany, Norway, Poland), USA, China (Hong 
Kong) and Australia. Enrolment was carried out during 5 northern and 
4 Southern Hemisphere influenza seasons. The study was performed 
in compliance with the principles of the Declaration of Helsinki and 
its amendments, and in accordance with Good Clinical Practice. The 
study protocol and amendments were approved by independent eth-
ics committees and institutional review boards at each centre.
2.2 | Patient inclusion and virological analysis
During this study period, the criteria for inclusion were as previ-
ously described.13 Briefly, patients >1 year of age, presenting 
within 48 hours after disease onset of influenza- like illness and/or 
a positive rapid test result for influenza were eligible for enrolment. 
Patients had throat or nasal swabs collected on days 1, 3 (self- swab), 
6 and 10 for real- time reverse transcription PCR (RT- PCR) analyses 
of influenza type, subtype and susceptibility to NAI. NAI suscepti-
bility was determined according to the IC50 values performed on 
the viruses by a chemiluminescent assay (NA- Star), and the measure 
of the fold increase observed as compared to IC50 values of sus-
ceptible strains, according to the common procedure.14,15 Resistant 
viruses were either with a reduced inhibition (RI) or a highly reduced 
inhibition (HRI), depending on the fold increase as per the WHO 
GISRS guidelines. The Day 10 evaluation was added to the protocol 
by an amendment in Year 2 of the study (2009). In cases of detec-
tion of resistance (by RT- PCR or by NAI assay), the viral load of 
both susceptible and resistant genotypes was compared through 
specific RT- PCR allowing the semi- quantification of wild- type and 
resistance- associated substitution at positions 275 for A(H1N1) vi-
ruses and 119 and 292 for A(H3N2) viruses. Similarly, the RT- PCR 
for the virus detection allowed virus quantification and respective 
loads estimations. Patients with mixed influenza A/influenza B and 
influenza A H1N1/influenza A H3N2 infections were excluded from 
the analysis. In addition, even if recruitment following previous NAI 
treatment was allowed, patients with previous NAI treatment were 
excluded from the analysis.
All Influenza- positive samples by RT- PCR were cultured on MDCK 
cells, and subsequently sequenced (haemagglutinin [HA] and neur-
aminidase [NA] gene segments) and phenotypically tested for NAI re-
sistance when possible, as previously described.16
2.3 | Patient clinical follow- up
Scores for 7 cardinal influenza symptoms (0 [absent], 1 [mild], 2 [mod-
erate], 3 [severe]) were recorded daily on diary cards by the patient 
(fever, sore throat, nasal congestion, cough, myalgia, fatigue and head-
ache), checked by the physician (days 1- 10), and summed to produce a 
total symptom score as previously described.13
2.4 | Biostatistical analysis
Kaplan- Meier plots were generated for time to viral RNA clearance 
and time to resolution of all diary card symptoms (no single symptom 
score of >1 on diary card). The statistical analysis was carried out by 
either Kruskal- Wallis or Wilcoxon signed- rank tests.
3  | RESULTS
During the 5- year surveillance period, 3230 patients with a single 
influenza strain infection were recruited. All study centres enrolled 
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patients, the majority of whom (75.3%) were from the Northern 
Hemisphere (Figure 1). Of 3230 RT- PCR- positive patients, 2316 had 
influenza A and 914 had influenza B. These latter B cases are not ana-
lysed in this study report. In addition, some patients were excluded 
because of mixed influenza A and B infection, previous oseltamivir 
treatment or missing data.
Among the 2316 influenza A- positive patients registered, 2147 
were eligible for analysis and 1216 received oseltamivir monother-
apy (52.5%) within 2 days of symptom onset (9 seasonal H1N1; 662 
H3N2; 545 H1N1pdm2009) (Figure 2: Flow chart).
Except for the 30 patients with the naturally resistant seasonal 
H1N1 included in 2008/9 (9 treated and 21 non- treated), antiviral 
resistance was detected by mutation- specific RT- PCR in Day 1 vi-
ruses from neither the 1207 treated patients nor the 910 non- treated 
patients. However, emergence of resistance (post- Day 1) was de-
tected by RT- PCR in 43/1207 of the oseltamivir- treated influenza A 
H1N1pdm09 or H3N2 patients (Figure 2: Flow chart). Most of these 
patients had a mixed susceptible/resistant genotype (Tables 1a,b, 2a 
and b).
As reported previously, the detection of resistance was significantly 
more frequent in the 1- to 5- year- old age group as compared with 
the combined older age groups (30/253 [11.85%] vs 13/909[1.43%]; 
P < .0001; Table 2). This was also observed when comparing the rate 
of resistance by subtype (16.1% vs 1.7% for H1N1pdm09 and 7.7% vs 
1.2% for H3N2). In addition, we observed an increase in detection of 
resistant influenza A viruses in the last 3 years, for both H3N2 (2/190 
[1.05%]; 4/97 [4.1%] and 10/326 [3%] in 2010/2011, 2011/2012 
and 2012/2013, respectively) and H1N1pdm09 (14/226 [6.2%]; 1/26 
[3.8%] and 9/57 [15.8%] in 2010/2011, 2011/2012 and 2012/2013, 
respectively), as compared with 0% (0/22) for H3N2 and 2/218 (0.9%) 
for H1N1pdm09 during the first 2 years of surveillance (Table 1a and 
b). The increased resistance in H3N2 viruses observed in the 3 last 
years, when the H3N2 incidence was higher, correlated with the emer-
gence of strains with V241I/N369K in NA combined with D114N/
S202D/S468N in the HA of H3 (data not shown). Overall, these 
changes in the NA and HA were related to the emergence of the new 
3C clade in 2011 (i.e A/Victoria/361/2011).
All 43 resistant viruses had acquired either the H275Y substi-
tution for N1 viruses (n = 27) or the R292K substitution for N2 vi-
ruses (n = 16). No other substitutions known to be associated with 
reduced sensitivity to NAI in human influenza viruses were detected 
when the Na- gene segment was sequenced from viruses obtained 
in culture on MDCK cells (i.e substitutions at positions E119, Q136, 
N142, T156 + D213, D198, I222, N294 and G320, sequence data not 
shown).
In 27/43 (62.8%) of samples in which resistance first appeared, 
viral loads were too low for phenotyping (Table 2a and b). Phenotypic 
characterization was performed on 16 resistant viruses, including 11 
H1N1pdm2009 and 5 H3N2. In 7 cases (5 H1N1pdm09 and 2 H3N2), 
the phenotypic characterization did not show IC50 values associated 
with either RI or HRI, likely because of mixed sensitive/resistant popu-
lations (IC50 ranging from 0.1 to 7.6 nmol L
−1, Table 2a and b).
In a significant number of cases (24/27 H1N1pdm2009 and 
15/16 H3N2), the resistant virus detected by the mutation- specific 
RT- PCR, contained a mixed population of H275/Y275 or R292/K292 
for at least one time point (Table 2a and b). In 22 of these cases (11 
H1N1pdm2009 and 11 H3N2), only the last PCR- positive specimen 
was with a resistant profile with a mixed S/R genotype.
During follow- up, 11 of the 43 patients (9/27 H1N1pdm2009 and 
2/16 H3N2) were still RT- PCR positive at Day 10 (as shown in Tables 2 
and 2b). Pairwise comparison of the 3 study groups (treated, non- treated 
and treated but with a resistant virus) showed that viral RNA was de-
tected for longer periods of time in nasal swabs samples collected from 
patients infected with oseltamivir- resistant viruses suggesting a delayed 
F IGURE  1 Geographic distribution 
and patient recruitment during years 1 
to 5 of the IRIS study. IRIS, the Influenza 
Resistance Information Study
4  |     LINA et AL.
virus clearance, with a median of 8.1 days for the treated patients vs 
9.9 days for the non- treated patients (P < .0001) and 10.9 days for the 
treated patients with a resistant virus (P < .0001) (Figure 3).
Similarly, the time to alleviation of symptoms was 1 day shorter in 
treated patients as compared with non- treated patients (P < .0001, see 
Figure 4). However, despite the delayed virus clearance observed in 
patients infected with oseltamivir- resistant viruses, this group exhib-
ited a shorter duration of symptoms (borderline significance: P = .024, 
Figure 4). Resistant viruses emerged during the treatment course. In 
all documented cases, the resistant virus remained detectable until 
the last positive detection, except for one H1N1pdm2009 (patient 11 
Table 2a) and 2 H3N2 cases that had a resistant genotype at Day 3 and 
Day 6, respectively, and a restored susceptible genotype detectable at 
Day 10 (patients 9 and 10 Table 2b).
4  | DISCUSSION
In years 1- 5 of the IRIS study, resistance to oseltamivir in influenza A 
viruses was not detected in the 2316 Day 1 samples analysed (except 
F IGURE  2 Flow chart of recruitment of patients included in the study. No trt, no treatment; H1N1s, Seasonal H1N1 circulating before the 
H1N1pdm09 2009 pandemic
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for one patient that was excluded because of prior antiviral treat-
ment, and 30 patients with the naturally resistant seasonal H1N1). 
This low rate of detection is consistent with the literature and recent 
reports from WHO, where resistance in initial samples is rarely re-
ported.15,17-19 This oseltamivir resistance was detected only in speci-
mens collected during the course of antiviral treatment, and mostly 
in patients aged 1- 5 years. Among 1207 patients with influenza A 
H1N1pdm09 and H3N2 viruses that have been investigated, resist-
ance was observed in 27 H1N1pdm09 and 16 H3N2 viruses, with 
the H275Y and R292K substitutions only, respectively, representing 
3.89% of the patients. In most cases, resistance was associated with a 
mixed susceptible/resistant virus population, reflecting a progressive 
selection of the resistant population during treatment. Besides H275Y 
and R292K, no other substitution associated with resistance was de-
tected in the NA. This suggests that as opposed to observations in 
immunocompromised, these 2 positions are almost the exclusive “hot 
spots” for changes associated with antiviral resistance in the context 
of oseltamivir pressure in immunocompetent patients.14,20
In our study, the proportion of R292K substitutions in H3N2 vi-
ruses isolated (16/662, 2.4%) was relatively low as compared to Kiso 
et al.21 The latter reported 9/50 (18%) of emerging resistant viruses 
during treatment in children with a first detection at day 4 of treat-
ment. In our study, we report only 7.7% (10/129) of emerging resis-
tance. This difference may be due to the recruitment of cases (majority 
of hospital cases in the Kiso study), the sampling procedures (nasal 
washes in some patients of the Kiso study vs swabs in our study) 
and the geographical distribution of our patients. However, we both 
 support the idea that monitoring the resistance of influenza viruses 
requires analysis of sequential specimens collected in patients treated 
with oseltamivir. Surveillance with D1 samples only cannot provide a 
clear picture for an emerging resistance risk assessment, especially for 
H3N2 viruses.
According to analysis of the sequential specimens collected in 
these patients, resistant viruses emerged by Day 3 of treatment from 
susceptible strains and were selected by oseltamivir. It is known that 
the fitness of R292K H3N2 viruses is putatively severely impaired.22 
This detection of the R292K substitution was performed by a spe-
cific snip RT- PCR, a sensitive method that can detect down to 5% 
of a minority species.15 It confirmed also that in most cases, a mixed 
population is detected, supporting the hypothesis that impaired NA 
activity of 292K viruses may be trans- complemented by the NA ac-
tivity of R292 bystander viruses, as it has been reported for mu-
tations at position 119.23 The mutation- specific real- time RT- PCR 
used in the current study and HA or NA sequencing were performed 
on the original clinical specimen and not culture based or genetically 
assessed by sequencing on culture material. In the present study, of 
the 16 samples in which the R292K mutation was detected, only 5 
could be cultured and subsequently tested phenotypically for NAI 
susceptibility. Two of them showed an increased IC50, while 3 had a 
normal IC50. This lack of detection of reduced inhibition may be due 
to the use of the Na- Star system (chemiluminescent assay) that is 
less sensitive than the gold standard MUNANA- based fluorescent 
assay.24
The H275Y resistance in H1N1pdm09 was the most reported in 
this study (27/43 R- Viruses). This is consistent with the various re-
ports about oseltamivir resistance in N1 viruses in general. This resis-
tance emerged from Day 3 in 1/3 of the 27 cases, not only in children 
(Table 2b). When, measured, the IC50 values were mostly reduced 
inhibition, and some were normal inhibition, due to mixed genotypes 
(H275 & 275Y) and the use of the chemiluminescent assay. The 
TABLE  1 Resistance mutations detected by RT- PCR in the 1207 influenza A- positive patients treated with oseltamivir, by study year and 
age group. (a) H1N1pdm09; (b) H3N2
Age group (y)
Detection frequency of H275Y substitution n/N (%)a
Negative RT- PCR at Day 10 
for H275Y viruses
Resistance 
rate (%)2008- 10 2010- 11 2011- 12 2012- 13
a
1- 5 1/48 (2.1) 12/53 (22.6) 1/5 (20.0) 6/18 (33.3) 15/20 20/124 (16.1)
6- 12 0/75 (0.0) 1/30 (3.3) 0/6 (0.0) 1/4 (25.0) 2/2 2/115 (1.7)
≥13 1/95 (1.1) 2/143 (1.4) 0/15 (0.0) 2/35 (5.7) 2/5 5/288 (1.7)
NA 0/18 (0)
Age group (y)
Detection frequency of R292K substitution n/N (%)a
Negative RT- PCR at Day 10 
for R292K viruses
Resistance 
rate (%)2008- 10 2010- 11 2011- 12 2012- 13
b
1- 5 0/1 (0.0) 1/36 (2.8) 2/16 (12.5) 7/76 (9.2) 1/10 10/129 (7.7)
6- 12 0/1 (0.0) 0/42 (0.0) 2/15 (13.3) 1/76 (1.3) 1/3 3/134 (2.2)
≥13 0/20 (0.0) 1/112 (0.9) 0/66 (0.0) 2/174 (1.2) 0/3 3/372 (0.8)
NA 0/27 (0)
n/N (%), number of viruses with mutation/Number of viruses tested (percentage).
NA missing data (age group and year of detection).
aThe 9 patients with A(H1N1)s virus are not listed in this table.
6  |     LINA et AL.
TABLE  2 Analysis of the kinetic of emergence of genotypic and phenotypic resistance during the study. (a) kinetics of emergence of the 
H275Y substitution in H1N1pdm09 viruses as detected by specific RT- PCR and measure of IC50 values, (b) kinetics of emergence of the R292K 
substitution and screening for E119V substitution in H3N2 viruses as detected by specific RT- PCR and measure of IC50 values
Patient Year Age Visit Virus load (log) H275 275Y
IC50 to 
oseltamivir
a
1 2009 13 Baseline 5,6 x
Day 3 3,7 x NA
Day 6 ND
Day 10 ND
2 2011 4 Baseline 6,6 x
Day 3 4,1 x
Day 6 2,8 x x NA
Day 10 ND
3 2011 1 Baseline 5,7 x
Day 3 4,5 x x NA
Day 6 3,7 x
Day 10 ND
4 2011 14 Baseline 6 x
Day 3 4,7 x
Day 6 3,8 x x 130 nmol L−1
Day 10 ND
5 2010 3 Baseline 6.3 x
Day 3 5.9 x
Day 6 4.5 x
Day 10 3.8 x x 68 nmol L−1
6 2011 1 Baseline 5.4 x
Day 3 5.6 x
Day 6 4.2 x x 74 nmol L−1
Day 10 4.4 x x 79 nmol L−1
7 2011 6 Baseline 6.8 x
Day 3 5.1 x
Day 6 2.1 x
Day 10 3.0 x x NA
8 2011 1 Baseline 5.4 x
Day 3 1.5 x
Day 6 3.9 x x 0.56 nmol L−1
Day 10 ND
9 2012 1 Baseline 5.8 x
Day 3 4.6 x
Day 6 x x NA
Day 10 ND
10 2013 4 Baseline 5.9 x
Day 3 4.5 x
Day 6 6.0 x x 100 nmol L−1
Day 10 ND
(Continues)
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Patient Year Age Visit Virus load (log) H275 275Y
IC50 to 
oseltamivir
11 2013 6 Baseline 7.5 x
Day 3 5.7 x x NA
Day 6 4.5 x x NA
Day10 3.6 x
12 2009 1 Baseline 7.2 x
Day 3 4.5 x x NA
Day 6 ND
Day10 ND
13 2011 2 Baseline 4.3 x
Day 3 3.0 x
Day 6 1.8 x x NA
Day10 ND
14 2012 38 Baseline 4.0 x
Day 3 4.0 x x NA
Day 6 2.6 x
Day 10 2.4 x NA
15 2012 2 Baseline 5.5 x
Day 3 2.0 x
Day 6 1.9 x NA
Day 10 ND
16 2012 1 Baseline 5.1 x
Day 3 4.7 x x BA
Day 6 3.6 x x 0.36 nmol L−1
Day 10 ND
17 2011 1 Baseline 7.2 x
Day 3 4.3 x
Day 6 4.3 x x 7.6 nmol L−1
Day 10 ND
18 2012 2 Baseline 5.4 x
Day 3 4.2 x
Day 6 4.0 x x NA
Day 10 ND
19 2013 3 Baseline 4.0 x
Day 3 5.5 x
Day 6 4.0 x x 93 nmol L−1
Day 10 ND
20 2013 55 Baseline 4.6 x
Day 3 5.1 x
Day 6 5.5 x x 86 nmol L−1
Day 10 2.7 x x NA
TABLE  2  (Continued)
(Continues)
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Patient Year Age Visit Virus load (log) H275 275Y
IC50 to 
oseltamivir
21 2011 2 Baseline 6.8 x
Day 3 5.7 x
Day 6 3.0 x NA
Day 10 3.1 x NA
22 2011 55 Baseline 6.6 x
Day 3 4.6 x x NA
Day 6 ND
Day 10 ND
23 2011 3 Baseline 5.7 x
Day 3 6.1 x
Day 6 3.1 x x NA
Day 10 ND
24 2011 5 Baseline 6.6 x
Day 3 2.9 x
Day 6 4.7 x X NA
Day 10 1.6 ? ? NA
25 2011 1 Baseline 2.7 x
Day 3 5.5 x x NA
Day 6 6.2 x x 1.1 nmol L−1
Day 10 ND
26 2011 1 Baseline 5.7 x
Day 3 5.7 x x NA
Day 6 5.4 x x 53 nmol L−1
Day 10 ND
27 2011 4 Baseline 6.0 x
Day 3 3.4 x
Day 6 3.3 x x NA
Day 10 x x NA
Patient Year Age Visit Virus load (log) 119E R292 292K
IC50 to  
oseltamivir
b
1 2011 2 Baseline 7.7 x x
Day 3 3.8 x x NA
Day 6 4.1 x x x
Day 10 ND
2 2012 4 Baseline 5.4 x x
Day 3 5.7 x x
Day 6 4.9 x x x NA
Day 10 ND
3 2013 2 Baseline 5.5 x x
Day 3 4.5 x x
Day 6 3.6 x x x NA
Day 10 ND
TABLE  2  (Continued)
(Continues)
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Patient Year Age Visit Virus load (log) 119E R292 292K
IC50 to  
oseltamivir
4 2012 4 Baseline 6.2 x x
Day 3 6.3 x x
Day 6 4.8 x x x >1000 nmol L−1
Day 10 ND
5 2012 66 Baseline 4.4 x x
Day 3 4.0 x x
Day 6 3.7 x x x NA
Day 10 ND
6 2013 4 Baseline 5.1 x x
Day 3 4.0 x x
Day 6 2.5 x x x NA
Day 10 ND
7 2010 20 Baseline 4.5 x x
Day 3 3.6 x x x NA
Day 6 ND
Day 10 ND
8 2011 7 Baseline 4.7 x x
Day 3 2.7 x x
Day 6 3.1 x x x NA
Day 10 ND x x
9 2012 6 Baseline 7.7 x x
Day 3 3.9 x x
Day 6 4.2 x x x NA
Day 10 3.9
10 2012 3 Baseline 5.2 x x
Day 3 4.5 x x
Day 6 4.8 x x x 0.29 nmol L−1
Day 10 3.0 x x
11 2012 41 Baseline 6.8 x x
Day 3 3.3 x x x NA
Day 6 ND NA
Day 10 ND
12 2012 4 Baseline 5.9 x x
Day 3 4.1 x x
Day 6 5.5 x x x >1000 nmol L−1
Day 10 ND
13 2012 7 Baseline 5.9 x x
Day 3 4.5 x x
Day 6 3.3 x x x NA
Day 10 ND
14 2012 2 Baseline 6.4 x x
Day 3 MISS
Day 6 3.9 x x x 0.1 nmol L−1
Day 10 ND
TABLE  2  (Continued)
(Continues)
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resistant Brisbane H1N1 that emerged in 2008 was supposed to be 
related to structural changes in the backbone of the NA that facili-
tated (imposed) the introduction of 275Y in the NA pocket to maintain 
both virus fitness and HA- NA balanced activities.11,25 In our study, 
the frequency of detection of resistance due to a 275Y substitution 
gradually increased during the surveillance, but the limited number of 
cases makes any interpretation difficult. According to the studies per-
formed recently, it seems that this path to a sustained 275Y virus in 
H1N1pdm09 as observed in 2008 for the Brisbane- like H1N1 has not 
started, but should be monitored.26,27
Post- treatment emergence of resistance in H1N1pdm09 appeared 
to be more frequent in the last 3 years, although with no statistically 
significant trend, possibly attributed to insufficient statistical power. 
This increase in resistance observed for H3N2 viruses cannot be de-
termined because of the limited number of patients enrolled in the 2 
first years. The apparent increase of 292K in the 2 most recent years 
coincided with the detection globally of a new 3C H3N2 clade.28 
Whether HA or NA mutations of the new clade 3C viruses that 
emerged during the 2011 influenza season relative to earlier Influenza 
A H3N2 clades increase the replicative capacity of R292K containing 
F IGURE  3 Time (days) from symptom onset to first laboratory record with influenza A RNA not detected. Pairwise comparisons between 
patients with no treatment vs patients treated with oseltamivir (within 48 hours of symptom onset) and vs treated patient with a resistant 
virus. Both treated and untreated populations included patients infected by influenza A viruses, with no detection of resistant viruses. *The 49 
resistant patients comprise 40 patients infected with H3N2 or H1N1pdm09 who developed resistance during the study plus 9 patients infected 
with seasonal H1N1. All 49 patients were in the treated group. Three patients (2 with H1N1pdm09 and one with H3N2) developed oseltamivir 
resistance during the study but were not treated until Day 3. These patients are not included in this comparison as they do not meet the 
definition
Study Groups N= Median (95% CI) Kruskal-Wallis Test
Treated Paents 1235 8.1 (7.9 to 8.4) p<0.0001
Treated & Resistant 49* 10.9 (10.0 to 11.9) P<0.001
Untreated 1004 9.9 (9.8 to 10.1) 
Treated v Treated & Resistant p<0.0001 (Wilcoxon Tests).
Patient Year Age Visit Virus load (log) 119E R292 292K
IC50 to  
oseltamivir
15 2011 3 Baseline 5.7 x x
Day 3 4.3 x x x NA
Day 6 3.7 x x
Day 10 ND
16 2011 2 Baseline 5.8 x x
Day 3 3.3 x x
Day 6 5.5 x x x 0.52 nmol L−1
Day 10 ND
NA, Not available (missing specimen); Neg, Influenza detection negative; NC, Not cultured or culture failed because of low viral load by RT- PCR (Ct>32).
IC50 values were obtained from virus culture and determined as oseltamivir concentration inhibiting NA activity as measured by a chemiluminescent assay 
(NA- Star), as described in the material and methods.
TABLE  2  (Continued)
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viruses similar to V241I/N369K in 2009pdmH1N1 for H275Y remains 
to be investigated. Similarly, there are no clues about Ha or Na substi-
tution that would increase the replicative capacity of 275Y containing 
H1N1pdm09 viruses.
Last, our results can also suggest a reduced risk of transmission 
a NAI- resistant virus when this resistance is developed during treat-
ment. We could document that, in most cases of this study, resistance 
was observed only in the last positive clinical specimen (30/43), when 
the viral load was significantly low. We can speculate that the risk of 
transmission is correlated with the viral shedding and concentration 
at the site of replication. So, even if we also observed that virus de-
tection (and shedding) was longer as compared with non- treated and 
treated patients (Figure 3), the risk of transmission of a resistant virus 
may be low.
This IRIS study is unique in providing a follow- up of resistance in 
a large population with direct and sensitive screening of clinical spec-
imens. Compared with other studies that have analysed the suscepti-
bility of influenza viruses at treatment onset, it provides detailed data 
on the risk of emergence of resistance in immunocompetent patients, 
with some hints regarding the possible emergence of resistance in vi-
ruses that display a genetic background favouring this emergence and 
its sustainability.
This study also confirms the lack of correlation between decreases 
in viral load and clinical outcome, especially when a resistant virus 
emerges.
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